Which Molecular Tests to Order for Colorectal Cancer
By MCL Education • November 19, 2019
Expires: November 19, 2021
By the end of this presentation, the audience will be able to describe the utility of microsatellite instability testing in colorectal cancer care and discuss the limitations of various assays used to diagnose microsatellite instability. The audience will also be able to describe the relevance of KRAS, NRAS, HRAS, and BRAF mutations in colorectal cancer care along with an approach to testing that ensures appropriate test utilization. Molecular alterations that predict responsiveness to currently available targeted therapies will also be discussed.
Rondell Graham, M.B.B.S. Associate Professor of Laboratory Medicine and Pathology Division of Anatomic Pathology Mayo Clinic, Rochester, Minnesota
Upon completion of this activity, participants should be able to:
Describe the clinical utility of microsatellite instability testing in colorectal cancer care.
Discuss the significance of KRAS, NRAS, HRAS, and BRAF mutations in colorectal cancer.
List alterations that predict responsiveness to currently available targeted therapies.
This webinar is designed for Oncologists, Pathologists, and Laboratory Directors.
The following types of credit are offered for this event: ASCLS P.A.C.E.®
Level of instruction for this program is intermediate.
To obtain credit:
Watch the video.
Complete the posttest and evaluation that launches immediately following the video.
Generate and print your certificate(s).
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 0.5 P.A.C.E.® contact hour.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.